Identification of asymptomatic *Entamoeba histolytica* infection by a serological screening test: A cross-sectional study of an HIV-negative men who have sex with men cohort in Japan

Yasuaki Yanagawa¹,², Rieko Shimogawara², Misao Takano¹, Takahiro Aoki¹, Daisuke Mizushima¹, Hiroyuki Gatanaga¹,³, Yoshimi Kikuchi¹, Shinichi Oka¹,³, Kenji Yagita², Koji Watanabe*¹,²

¹ AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan, ² Department of Parasitology, National Institutes of Infectious Diseases, Tokyo, Japan, ³ Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

*kwatanab@acc.ncgm.go.jp

Abstract

Background

Amebiasis, caused by *Entamoeba histolytica*, is spreading in developing countries and in many developed countries as a sexually transmitted infection. Here, we evaluated the efficacy of serological screening to identify asymptomatic *E. histolytica* infection as a potential epidemiological control measure to limit its spread.

Methodology/Principal findings

This cross-sectional study was carried out between January and March 2021 in an HIV-negative men who have sex with men (MSM) cohort at the National Center for Global Health and Medicine. Serological screening was performed using a commercially available ELISA kit. For seropositive individuals, we performed stool polymerase chain reaction (PCR) to determine current *E. histolytica* infection. We performed *E. histolytica* serological screening of 312 participants. None had a history of *E. histolytica* infection prior to the study. The overall *E. histolytica* seropositivity was 6.7% (21/312), which was similar to that found by the rapid plasma reagin test (17/312). We identified current infection in 8 of 20 seropositive participants (40.0%) by stool PCR.

Conclusions/Significance

Our serological screening approach constitutes a potentially practical epidemiological strategy. Active epidemiological surveys, in combination with an effective screening strategy for asymptotically infected individuals, should be applied to help reduce sexually transmitted *E. histolytica* infections.
Author summary

Amebiasis, caused by *Entamoeba histolytica*, is now spreading not only in developing countries, but also in many of developed countries. Unlike the situation in developing countries, transmission occurs directly from one infected person to another via sexual contact, called sexually transmitted *E. histolytica* infection. Furthermore, most cases of *E. histolytica* infection are asymptomatic, who can be a reservoir for sexual transmission in the community. Cost-effective epidemiological strategy is urgently needed. Hereby, we performed a serological test for 312 “asymptomatic” HIV-negative men who have sex with men to assess the effective screening method for *E. histolytica* infection. We identified 21 seropositive samples (6.7% of seropositivity, 21/312), in which relatively high seropositivity to *E. histolytica* was seen among the participants with positive serology for Treponema pallidum hemagglutination (TPHA) or hepatitis B core antibody (HBcAb). Finally, we identified current infection (asymptomatic *E. histolytica* infection) in 8 out of 20 stool sampling cases (40.0%) by polymerase chain reaction. Our serological screening assay provides a potentially practical epidemiological strategy. Active epidemiological survey, in combination with the effective screening strategy for asymptomatically infected individuals are considered for the future control of sexually transmitted *E. histolytica* infection.

Introduction

Amebiasis is an intestinal protozoa infection caused by *Entamoeba histolytica*, which is the second most common cause of parasite-related deaths worldwide and is particularly found in developing countries [1]. It is also a growing concern in some developed countries in East Asia and Europe, where *E. histolytica* infection is increasingly prevalent as a sexually transmitted infection [2–4]. In Japan, men who have sex with men (MSM) are reported to be at especially high risk for sexually transmitted *E. histolytica* infection [5,6]. Life-threatening cases of *E. histolytica* infection are accumulating in these countries [7–9]. Moreover, many of these cases were not diagnosed until autopsy [9]. This is likely because *E. histolytica* infection is a neglected disease; thus, it is rarely suspected in the clinical setting when a patient has acute abdominal symptoms. Hence, an effective epidemiological strategy to reduce *E. histolytica* infections is urgently needed. In developing countries, transmission typically occurs as a result of unsanitary conditions; however, transmission can also directly occur between people through sexual contact [10]. Furthermore, most cases of *E. histolytica* are asymptomatic [11]. Indeed, seroprevalence data has shown that asymptomatic infection occurs among sexually active individuals [12,13] who act as a reservoir for sexual transmission. Polymerase chain reaction (PCR) using stool samples is the best method for detecting *E. histolytica* infection [11]; however, it is expensive, time-consuming and requires complicated procedures and is thus not ideal as a screening method. Moreover, the handling of stool samples at voluntary counselling and testing centres in developed countries is inconvenient; most sexually transmitted infection (STI) screening tests at these centres are performed using blood samples. Although the screening utility of serology for asymptomatic *E. histolytica* infected carriers has not been assessed in previous studies, our recent data strongly suggest that serological testing is highly sensitive for detecting symptomatic infectious diseases and asymptomatic *E. histolytica* infection [14].
Here, we prospectively performed serological testing for HIV-negative men who have sex with men (MSM) and confirmed *E. histolytica* infection by PCR for those with positive serology. We also assessed the utility of serological screening for the identification of asymptomatic *E. histolytica* infection.

**Methods**

**Ethics statement**

This study was approved by the ethics committee of the Center (NCGM-G-002091-00), and all participants provided written informed consent in accordance with the Declaration of Helsinki. All participants gave written informed consent for the study.

**Study population**

This cross-sectional study was carried out between January and March 2021 in an HIV-negative MSM cohort at the Sexual Health Clinic of the National Center for Global Health and Medicine (NCGM) [15]. This cohort was a single-centre prospective study. It was established to perform HIV screening and serological testing for syphilis and rectal *Chlamydia trachomatis* and *Neisseria gonorrhoeae* every 3 months for HIV-negative MSM in 2017. Inclusion criteria of the HIV-negative cohort were MSM, aged ≥16 years old, those who have anal sexual intercourse. People diagnosed with HIV at enrolment were excluded from the cohort and were referred to an HIV-positive clinic, the AIDS Clinical Center at NCGM, or other medical institutions.

**Sample size estimation**

Sample size estimation to assess the seropositivity of *E. histolytica* among a sexually active MSM population in the study site was performed using Power Analysis & Sample Size 2021 (NCSS Statistical Software, LLC, Utah, USA). The minimum number of necessary samples was estimated as 255 participants. The following numbers were used for the calculation: confidence level 95%, precision, half width 5%, population proportion 21.3%, and population size 24,452 people. The population proportion was estimated using the previously reported seropositivity of *E. histolytica* among HIV-positive MSM [12]. The population size (MSM at study location) was calculated based on the data of 1.2% of Japanese males having sex with men during their life span [16], and that of 2,037,693 males between 21 and 50 years old living in the metropolitan Tokyo area ([https://www.toukei.metro.tokyo.lg.jp/juuki-y/2021/jy21q10601.htm#kubu](https://www.toukei.metro.tokyo.lg.jp/juuki-y/2021/jy21q10601.htm#kubu)).

**Serum anti-*E. histolytica* testing**

The presence of anti-*E. histolytica* antibody was detected using a commercially available ELISA kit (*Entamoeba histolytica* IgG-ELISA; GenWay Biotech, Inc., San Diego, CA, USA). All procedures were performed according to the manufacturer’s instructions. In brief, diluted serum samples (100X dilution in IgG sample diluent) as well as 5 control samples, consisting of 1 substrate blank, 1 negative control, 2 cut-off controls, and 1 positive control, were applied to 96-well plates pre-treated with *E. histolytica* antigen and incubated at 37˚C for 1 hour. After washing the plates using washing solution, 100 μL of *E. histolytica* Protein A conjugate was added to all wells except the substrate blank and incubated for 30 minutes in the dark. After a second wash, TMB (3,3’-5,5’-Tetramethylbenzidine) substrate solution was added to all wells. After a 15-minute incubation, 100 μL of stop solution was applied to the plates, and absorbance of the specimen was then read at 450/620 nm using a spectrometer. The ELISA titer was calculated by employing correction to obtain the cut-off value [formula used for the
correction: units = (sample absorbance value × 10) / (cut-off absorbance value)]. Positive results were interpreted as 11 units or higher.

**Identification of Entamoeba from stool samples**

For seropositive participants, stool samples were obtained and examined by stool ova and parasite examination (O&P), which consisted of direct microscopic examination for trophozoites and formalin-ether sedimentation for cyst forms stained with iodine. A single-round conventional PCR (cPCR) assay for the detection of three *Entamoeba* species (*E. histolytica*, *E. dispar*, and *E. moshkovskii*) was carried out. Stool specimens (approximately 0.2 g) were weighed and subjected to DNA extraction using a QIAamp Fast DNA Stool Mini Kit (Qiagen, Hilden, Germany). DNA extraction was performed according to the manufacturer’s instructions. The DNA was eluted in 100 μL of elution buffer (Qiagen) and stored at −80˚C until further analysis. The primer set was designed based on signature sequences in the small-subunit rRNA of each species, of which the utility was confirmed in a previous study [17]. The primer set consisted of the same forward primer (EngF, 5’-ATGCACGAGAGCGA AGCAT-3’) in combination with three reverse primers, one for each of the three species (EhR, 5’-GATCTAGAAAC AATGCTTCTCT-3’; EdR, 5’-CACCACCTTACTACC-3’; EmR, 5’-CACCACCTTACTACC ATCCCTACC-3’). *Entamoeba* species were differentiated based on the sizes of the PCR products (a 166-bp PCR product for *E. histolytica*, a 752-bp PCR product for *E. dispar*, and a 580-bp PCR product for *E. moshkovskii*). Finally, the results were confirmed by DNA sequencing. Sanger sequencing was performed with a BigDye Terminator v3.1 Cycle Sequencing kit (Thermo Fisher Scientific Inc., Tokyo, Japan), and then analysed on an ABI 3730xl DNA Analyzer (Thermo Fisher Scientific Inc., Tokyo, Japan).

**Measurements of other STI testing**

Hepatitis B surface antigen, core antibody, and hepatitis C antibody were tested by a chemiluminescent enzyme immunoassay (CLEIA)-based HISCL analyser with HISCL kits (Sysmex Corp. Japan). Serum rapid plasma reagin test (RPR) [“Sankoh” (EIDIA Co, Tokyo)] and *Treponema pallidum* latex hemagglutination assay (TPHA) were performed. The diagnosis of syphilis was based on serum RPR ≥8 and positive TPHA results. A nucleic acid amplification test (Bio Medical Laboratories, Inc., Tokyo, Japan) was used to detect *Chlamydia trachomatis* and *Neisseria gonorrhoeae*.

**Statistical analyses**

Comparisons of the qualitative data were carried out with the Chi-square test, and analysis of variance (ANOVA) was used for comparisons of quantitative data. Statistical significance was defined as a two-sided P value < 0.05. All statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA, USA).

**Results**

In total, serological testing for *E. histolytica* was performed for 312 asymptomatic HIV-negative MSM (Fig 1). Of these, 91.3% had only male-to-male sexual contact, while the other 8.7% had bisexual contact (Table 1 and S1 Data). More than half of the participants (158/312) had experienced STIs prior to the present study, although none had a history of treatment for *E. histolytica* infection based on a medical self-declaration form. The overall seropositivity of *E. histolytica* was 6.7% (21/312) (Fig 2A and S2 Data). This was the same positivity as found by RPR testing 5.4% (17/312), in which only four people showed high RPR titres (R.U. > 16.0).
Additionally, *E. histolytica* seropositivity was significantly higher than that of hepatitis B surface antigen and hepatitis C virus antibody. The *E. histolytica* seropositivity was positively correlated with age (Fig 2B). There was no significant correlation between the *E. histolytica*

![Study workflow](https://doi.org/10.1371/journal.pntd.0009793.g001)

![Asymptomatic but seropositive for *E. histolytica* (N=21)](https://doi.org/10.1371/journal.pntd.0009793.t001)

Table 1. Characteristics of study participants undergoing a screening test for anti-*E. histolytica* antibody.

| Median [IQR] or % (N) | All (N = 312) |
|-----------------------|--------------|
| Age                   | 34 [28–41]   |
| Sexual partners        |              |
| Male only              | 91.3% (282/309) |
| Male and female        | 8.7% (27/309) |
| Insertive/receptive    |              |
| Insertive only         | 19.5% (60/308) |
| Receptive only         | 26.9% (83/308) |
| Both                   | 51.0% (157/308) |
| No insertive sex       | 2.3% (8/308) |
| Number of sexual partners within 6 months | 5 [3–10] |
| Condom use (%)         | 60 [20–90]   |
| Past treatment of any STIs | 50.6% (158/312) * |
| Past treatment of amebiasis | 0% |

Abbreviations: IQR, inter quartile range; N, number; STIs sexually transmitted infections; AmebaAb, anti-*Entamoeba histolytica* antibody.

*List of past STIs consisted of syphilis (n = 51 cases), *Chlamydia trachomatis* infection (n = 40 cases), condyloma acuminata (n = 33 cases), *Neisseria gonorrhoeae* (n = 26 cases), hepatitis B virus infection (n = 22 cases), pubic lice (n = 22 cases), genital herpes infection (n = 11 cases), hepatitis A virus infection (n = 4 cases), *Mycoplasma genitalium* infection (n = 2 cases), and giardiasis (n = 2 cases) (S3 Data).

[https://doi.org/10.1371/journal.pntd.0009793.t001](https://doi.org/10.1371/journal.pntd.0009793.t001)
Fig 2. *Entamoeba histolytica* seropositivity and screening results of other sexually transmitted infections. (A) Seropositivity of sexually transmitted infections (solid bars) compared with that of *Entamoeba histolytica* (clear bar) by Fisher’s exact test. (B) *E. histolytica* seropositivity by age group. The ratio of PCR-positive cases to seropositive cases is indicated by the solid bar. (C) *E. histolytica* seropositivity in those with and without other sexually transmitted infections. Error bars indicate 95% confidence intervals. Abbreviations: AmebaAb, anti-*Entamoeba histolytica* antibody; RPR, rapid plasma regain; TPHA, *Treponema pallidum* hemagglutination; HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B core antibody; HCVAb, hepatitis C virus antibody; PCR, polymerase chain reaction; Ct, *Chlamydia trachomatis*; Ng, *Neisseria gonorrhoeae*; REF, reference data; NS, not significant.

https://doi.org/10.1371/journal.pntd.0009793.g002
seropositivity and sexual preferences of participants (S2 Data). As expected, E. histolytica seropositivity was relatively high among participants with positive serology for Treponema pallidum hemagglutination or hepatitis B core antibody and among those with Chlamydia trachomatis and/or Neisseria gonorrhoeae infection (Fig 2C).

Next, to assess current asymptomatic infections among individuals who were seropositive for E. histolytica, we performed O&P and PCR of the stool samples to identify the pathogen. One of the 21 seropositive individuals refused stool examination; therefore, we examined a total of 20 stool samples. None of these seropositive individuals had abdominal symptoms at the time of stool sampling. O&P identified cysts in 20% (4/20) of the seropositive participants (cysts in three cases and cysts and trophozoites in one case). PCR identified E. histolytica DNA in 40.0% (8/20) of the seropositive participants. Interestingly, one person with cysts had a negative PCR result; this was concluded to be a false-positive by O&P. Thus, we finally identified 8 cases of asymptomatic E. histolytica infection in 20 seropositive participants of the 312 HIV-negative MSM cohort.

Discussion
In the present study, serological testing to identify E. histolytica infection was performed for HIV-negative MSM individuals. The overall seropositivity (6.7%) was between that found in HIV-positive individuals (21.3%) [12] and that at a voluntary counselling and testing centre in Tokyo (2.6%) [13], even though no participants had a previous treatment history of E. histolytica infection at inclusion. This indicates that E. histolytica infection is a common STI among HIV-negative MSM individuals. We also identified current E. histolytica infection in 40% of seropositive individuals. This finding is consistent with a previous study that found a 38.9% (7/18) serological testing specificity against colonoscopically identified asymptomatic amoebic colitis [17]. On the basis of the results calculated by dividing 1 by the positive ratio of each test, 37.1 serologic tests followed by 2.5 stool PCR tests were required for the identification of one case of asymptomatic infection in this study population. This is the first study showing that mass-screening by serology can identify new cases of asymptomatic E. histolytica infection in a high-risk population.

There are some limitations to this study. First, we performed stool PCR testing only for seropositive participants because of limited funding. We were unable to assess serology false-negatives; however, our previous study using colonoscopy found that the false-negative rate is low (1.9%, 1/53) [18]. The sensitivity and specificity of serological testing to identify asymptomatic infection (effectiveness of the serological screening strategy for asymptomatic E. histolytica infection) should be confirmed by a future prospective analysis study, which performs stool PCR and serology for all participants. Second, owing to the small sample size, the epidemiological impact of the applied screening strategy for identifying asymptatically infected individuals could not be assessed. Our serological screening approach provides a potential strategy for the epidemiological control of re-emerging sexually transmitted E. histolytica infection. However, active epidemiological surveys to identify high-risk populations are also essential for the future epidemiological control of sexually transmitted E. histolytica infection.

In conclusion, we identified eight patients with E. histolytica infection from 312 asymptomatic HIV-negative MSM individuals by serological screening. Active epidemiological surveys, in combination with an effective screening strategy to identify asymptatically infected individuals, should be considered for the future control of this re-emerging communicable disease.

Supporting information
S1 Data. Comparison of characteristics between antibody positive and negative participants.
(DOCX)
S2 Data. E. histolytica seropositivity and sexual preferences of participants. There were no significant correlations between the seropositivity and sexual preferences by Fisher’s exact test or ANOVA test. Error bars indicate 95% confidence intervals. Abbreviations: E. histolytica, Entamoeba histolytica; STI, sexually transmitted infection; Tx, treatment history; NS, not significant.

(TIF)

S3 Data. Data set of characteristics and test results of study participants.

(XLSX)

Acknowledgments

We thank all of the medical staff who assisted with sample collection at the National Center for Global Health and Medicine Sexual Health Clinic. We also thank Katherine Thielges and J. Ludovic Croxford, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Author Contributions

Conceptualization: Koji Watanabe.
Data curation: Misao Takano, Takahiro Aoki, Daisuke Mizushima, Kenji Yagita.
Formal analysis: Yasuaki Yanagawa, Rieko Shimogawara, Kenji Yagita, Koji Watanabe.
Funding acquisition: Koji Watanabe.
Investigation: Yasuaki Yanagawa, Rieko Shimogawara, Kenji Yagita, Koji Watanabe.
Methodology: Rieko Shimogawara, Koji Watanabe.
Project administration: Koji Watanabe.
Resources: Misao Takano, Takahiro Aoki, Daisuke Mizushima.
Supervision: Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka, Kenji Yagita, Koji Watanabe.
Visualization: Yasuaki Yanagawa, Koji Watanabe.
Writing – original draft: Yasuaki Yanagawa.
Writing – review & editing: Hiroyuki Gatanaga, Yoshimi Kikuchi, Shinichi Oka, Kenji Yagita, Koji Watanabe.

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2095–2128. https://doi.org/10.1016/S0140-6736(12)61728-0 PMID: 23245604
2. Billet AC, Rousseau AS, Piroth L, Martins C. An underestimated sexually transmitted infection: amoebiasis. BMJ Case Rep. 2019; 12(5): e228942. https://doi.org/10.1136/bcr-2018-228942 PMID: 31079045
3. Hung CC, Chang SY, Ji DD. Entamoeba histolytica infection in men who have sex with men. Lancet Infect Dis. 2012; 12(9): 729–736. https://doi.org/10.1016/S1473-3099(12)70147-0 PMID: 22917103
4. Escola-Verge L, Arando M, Vali M, Rovira R, Espasa M, Sulleiro E, et al. Outbreak of intestinal amoebiasis among men who have sex with men, Barcelona (Spain), October 2016 and January 2017. Euro
5. Ishikane M, Arima Y, Kanayama A, Takahashi T, Yamagishi T, Yahata Y, et al. Epidemiology of Domestically Acquired Amebiasis in Japan, 2000–2013. Am J Trop Med Hyg. 2016; 94: 1008–1014. https://doi.org/10.4269/ajtmh.15-0560 PMID: 26976888

6. Yoshikura H. A strong correlation between the annual incidence of amebiasis and homosexual human immunodeficiency virus type infection in men. Jpn J Infect Dis. 2016; 69: 266–269. https://doi.org/10.7883/yoken.JJID.2015.420 PMID: 26743150

7. Shijubou N, Sumi T, Kamada K, Sawai T, Yamada Y, Ikeda T, et al. Fulminant amebic colitis in a patient with concomitant cytomegalovirus infection after systemic steroid therapy: A case report. World J Clin Cases. 2021; 9(15): 3726–3732. https://doi.org/10.12998/wjcc.v9.i15.3726 PMID: 34046476

8. Chahine E, Baghdady R, Chahine C, Doghmán G, El Kary N, El Khoury L, et al. Complete resolution of obstructive colonic amebic pseudotumor with conservative treatment: A case report and literature review. Int J Surg Case Rep. 2019; 59: 1–3. https://doi.org/10.1016/j.ijscr.2019.04.046 PMID: 31085385

9. Tomino T, Ninomiya M, Minagawa R, Matono R, Oshiro Y, Kitahara D, et al. Lethal multiple colon necrosis and perforation due to fulminant amoebic colitis: a surgical case report and literature review. Surg Case Rep. 2021; 7(1): 27. https://doi.org/10.1186/s40792-020-01095-2 PMID: 33469722

10. Hung CC, Wu PY, Chang SY, Ji DD, Sun HY, Liu WC, et al. Amebiasis among persons who sought voluntary counseling and testing for human immunodeficiency virus infection: a case-control study. Am J Trop Med Hyg. 2011; 84(1): 65–69. https://doi.org/10.4269/ajtmh.2011.10-0238 PMID: 21212204

11. Haque R, Huston CD, Hughes M, Houpt E, Petri WA Jr. Amebiasis. N Engl J Med. 2003; 348(16): 1565–1573. https://doi.org/10.1056/NEJMra022710 PMID: 12700377

12. Watanabe K, Aoki T, Nagata N, Tanuma J, Kikuchi Y, Oka S, et al. Clinical significance of high anti-Entamoeba histolytica antibody titer in asymptomatic HIV-1-infected individuals. J Infect Dis. 2014; 209(11): 1801–1807. https://doi.org/10.1093/infdis/jit815 PMID: 24338349

13. Yanagawa Y, Nagashima M, Gatanaga H, Kikuchi Y, Oka S, Yokoyama K, et al. Seroprevalence of Entamoeba histolytica at a voluntary counselling and testing centre in Tokyo: a cross-sectional study. BMJ Open. 2020; 10(2): e031605. https://doi.org/10.1136/bmjopen-2019-031605 PMID: 32102805

14. Yanagawa Y, Nagata N, Yagita K, Watanabe K, Okubo H, Kikuchi Y, et al. Clinical features and gut microbiome of asymptomatic Entamoeba histolytica infection. Clin Infect Dis. 2020;ciaa820.

15. Mizushima D, Takano M, Uemura H, Yanagawa Y, Aoki T, Watanabe K, et al. High prevalence and incidence of rectal Chlamydia infection among men who have sex with men in Japan. PLoS One. 2019; 14(12): e0220072. https://doi.org/10.1371/journal.pone.0220072 PMID: 31821348

16. Kihara M, a group of Ministry of Health. National survey of the knowledge about HIV/AIDS, sexual behaviour, and sexual consciousness of Japanese people. Yearbook of the National Survey of Educational Questionnaire. 2001; 94–105. No abstract available, written in Japanese.

17. Hamzah Z, Petmir S, Munthim N, Leelayooova S, Chavalitshewinkoon-Petrmir P. Differential detection of Entamoeba histolytica, Entamoeba dispar, and Entamoeba moshkovskii by a single-round PCR assay. J Clin Microbiol. 2006; 44(9): 3196–3200. https://doi.org/10.1128/JCM.00778-06 PMID: 16954247

18. Watanabe K, Nagata N, Sekine K, Watanabe K, Igari T, Tanuma J, et al. Asymptomatic intestinal amebiasis in Japanese HIV-1-infected individuals. Am J Trop Med Hyg. 2014; 91(4): 816–820. https://doi.org/10.4269/ajtmh.14-0278 PMID: 25048374